Published 11/03/2009 by RTTNews.com
Idenix Pharma Begins Phase II Clinical Trial Evaluating IDX184 For Treatment Of Hepatitis C Virus - Quick Facts
(RTTNews) - Idenix Pharmaceuticals, Inc. (IDIX: News ) said it has commenced Phase II clinical trial evaluating IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV, in combination with pegylated interferon and ribavirin, in treatment-naive hepatitis...
Share this
There are no more reports on this story yet.